$0.01 -$0.01 (-32.8%)

10:09 AM EST on 11/14/19

PONIARD PHARMACEUT COM STK USD0.02 (NASDAQOTH:PARD)

CAPS Rating: No stars

A biotechnology company focused on the discovery, development and commercialization of cancer therapy products.

Current Price $0.01 Mkt Cap $27,284.00
Open $0.01 P/E Ratio 0.00
Prev. Close $0.02 Div. (Yield) $0.00 (0.0%)
Daily Range $0.01 - $0.01 Volume 10
52-Wk Range $0.01 - $0.08 Avg. Daily Vol. 2,119

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

45 Outperform
9 Underperform
 

All-Star Players

5 Outperform
3 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top NASDAQOTH:PARD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

noirblood (40.94)
Submitted August 10, 2010

Lost a few points here with impatient timing, but I expect to gain them back and then some before the end of 2010.Baby bios are always hit or miss, but under a dollar PARD is worth a gamble. Their entire future depends on their next steps with… More

zzlangerhans (99.79)
Submitted January 21, 2011

I've worked Poniard hard to assume my rightful position at the top of the leaderboard, since my original negative call on the SPEAR trial in 2009 couldn't compete with the players who stochastically red-thumbed the Bottle Imp at the top. Over the… More

NASDAQOTH:PARD VS S&P 500 (SPY)

Fools bullish on NASDAQOTH:PARD are also bullish on:

Fools bearish on NASDAQOTH:PARD are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about PARD.

Recs

2
Member Avatar noirblood (40.94) Submitted: 8/10/2010 2:25:43 PM : Outperform Start Price: $25.07 NASDAQ OTHER:PARD Score: -273.63

Lost a few points here with impatient timing, but I expect to gain them back and then some before the end of 2010.

Baby bios are always hit or miss, but under a dollar PARD is worth a gamble. Their entire future depends on their next steps with Picoplatin, a late-stage anticancer compound designed for use against solid tumors.

Here are the key statements in their Q2 2010 earnings call in regards to Picoplatin's potential and the financial status of the company

Financials:

- "We continue to believe that our total cash and investment securities will be adequate to fund our operations while satisfying the minimum cash requirements of our loan facility, at least to the end of 2010."

- "First, we are working with the Healthcare Investment Bank, Leerink Swann, to evaluate our strategic alternatives including a potential corporate merger, sale of the company, partnerships or financing."

- "At June 30, 2010, we had total cash and investment securities of $29.3 million. Net cash used in operations for the second quarter was $7 million."

Picoplatin:

- "Platinum-based chemotherapeutics continue to be the stand of care for the treatment of solid tumors such as colorectal, lung and ovarian cancers. Picoplatin was rationally designed to overcome a variety of platinum-resistence mechanisms and as such, we believe, may have significant potential within indications where a platinum agent was previously utilized."

- "Importantly, Picoplatin demonstrated an overall survival benefit among 294 patients who were relapsed or refractory within 45 days of first-line platinum-based chemotherapy."

- "In this population, patients in the Picoplatin treatment arm experienced an overall survival of 21.3 weeks compared to 18.4 weeks for those receiving best supportive care alone resulting in a P-value of 0.0173."

- "We believe Picoplatin addresses a major unmet medical need in the treatment of second-line small-cell lung cancer as there is currently no FDA approved therapy for patients who are refractory or relapsed within 45 days of first-line platinum-based therapy."

- "Among the 273 patients who did not receive post-study chemotherapy, there was a statistically significant difference in overall survival in favor of Picoplatin with a P-value of 0.0345 with an overall survival of 18.3 weeks in the Picoplatin arm compared to 14.4 weeks among individuals receiving best-supportive care alone."

- "There was a statistically significant difference on an intend-to-treat basis in favor of Picoplatin for two important and clinical relevant measure; progression-free survival, or PFS, and time-to-progression, or TTP. Study findings demonstrated a PFS of 9 weeks in the Picoplatin arm compared to 6.6 weeks in the best-supportive care arm, with the P-value of 0.0281, and a median time to progression of 11.3 weeks in the Picoplatin arm versus 6.7 weeks in the best-supportive care arm with a P-value of 0.0002."

- "[In regard to prostate cancer] patients treated with Picoplatin in combination with docetaxel and prednisone experience a clinically meaningful overall survival of 21.4 months as compared to data from published literature which shows an overall survival benefit of 18.9 months for patients who receive standard-of-care treatment or docetaxel and prednisone alone."

- "These results reinforce the value proposition for Picoplatin and provide critical insights on the potential path forward in small cell lung cancer. We continue to work with our clinical advisors and with regulatory health authorities to develop a strategic plan to move Picoplatin in to registration trials in this indication as well as three other solid-tumor indications; colorectal, prostate and ovarian cancers."

Place your bets...

Recs

0
Member Avatar Killtank (< 20) Submitted: 11/9/2009 8:34:11 AM : Outperform Start Price: $329.20 NASDAQ OTHER:PARD Score: -286.07

gambling on phase III regarding Picoplatin for SCLC.

Recs

0
Member Avatar howie1pt5 (< 20) Submitted: 10/18/2007 11:48:05 AM : Outperform Start Price: $229.60 NASDAQ OTHER:PARD Score: -210.92

In phase 3 clinical trials for cancer medicine. Upon approval should drive price to $10 and above. Right now on fast track to approval.

Leaderboard

Find the members with the highest scoring picks in PARD.

Score Leader

salesgenieshort

salesgenieshort (< 20) Score: +295.45

The Score Leader is the player with the highest score across all their picks in PARD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
salesgenieshort < 20 10/6/2008 Underperform 5Y $166.80 -99.99% +195.70% +295.69 0 Comment
BuyTheDip 41.62 10/12/2009 Underperform 5Y $274.40 -100.00% +186.58% +286.58 0 Comment
TrackJimKramer 39.82 10/19/2009 Underperform 5Y $279.20 -100.00% +183.14% +283.13 0 Comment
MSFOBV1YH 99.32 11/10/2009 Underperform 5Y $338.00 -100.00% +182.52% +282.51 0 Comment
longtermgrowth09 < 20 8/3/2010 Underperform 5Y $26.40 -99.95% +174.33% +274.29 0 Comment
tjcardinal 51.87 9/19/2008 9/19/2008 Underperform 3W $192.00 -99.99% +148.99% +248.98 0 Comment
quiteman2 42.68 6/26/2008 Underperform 3M $180.00 -99.99% +144.05% +244.05 0 Comment
hawkutah2 80.20 12/13/2006 Underperform 3M $236.00 -99.99% +130.46% +230.46 0 Comment
howie1pt5 < 20 10/18/2007 Outperform 3Y $229.60 -99.99% +110.92% -210.92 1 Comment
myersfield < 20 9/20/2007 Outperform 1Y $225.60 -99.99% +113.05% -213.04 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PARD.